Yuekang Pharmaceutical: Subsidiary YKYY033 injection has been approved for new indications for clinical trials.

Yu Kang Pharmaceutical announced that its subsidiaries Beijing Yu Kang Ke Chuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd. recently obtained the approval notice for the clinical trial of YKYY033 injection issued by the National Medical Products Administration. This drug is used to treat deep vein thrombosis in adults, reducing the risk of recurrent DVT and pulmonary embolism after acute DVT; for patients with non-valvular atrial fibrillation, to reduce the risk of stroke and systemic embolism; for patients with chronic coronary artery disease and/or peripheral artery disease, to reduce the risk of major cardiovascular events; to prevent major thrombotic vascular events in patients with end-stage kidney disease; and for the treatment and secondary prevention of tumor-related venous thromboembolism. The company will conduct Phase I clinical trials of this product.